CATALYST PHARMACEUTICALS, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $0 $0 $500k $102.3m $118.7m $140.8m $214.2m $398.2m $491.7m $589.0m
Cost of Revenue $73k $14.8m $17.0m $21.9m $34.4m $52.0m $68.8m $87.3m
Cost of sales $73k $14.8m $17.0m $21.9m $34.4m $52.0m $68.8m $87.3m
Gross Profit (Calculated) (derived) $427k $87.5m $101.7m $118.9m $179.8m $346.2m $422.9m $501.7m
Research and development $11.4m $11.4m $19.9m $18.8m $16.5m $16.9m $19.8m $93.2m $12.6m $12.7m
Selling, general and administrative $15.9m $36.9m $44.2m $49.6m $58.2m $133.7m $177.7m $193.8m
Operating Expenses $19.3m $18.7m $35.8m $190.4m $206.5m
Total operating costs and expenses $19.3m $18.7m $35.8m $70.5m $77.8m $88.4m $112.4m $311.4m $296.6m $331.2m
Operating Income (Loss) ($19.3m) ($18.7m) ($35.3m) $31.8m $41.3m $52.4m $101.8m $86.8m $195.1m $257.8m
Additional Financial Items
Amortization of Intangible Assets $0 $1.1m $32.6m $37.4m $37.5m
Income (Loss) from Continuing Operations before Income Taxes, Domestic $283.5m
Other income, net $322k $454k $1.3m $1.6m $587k $282k $2.9m $7.7m $21.1m $25.7m
Income tax provision $0 $0 $0 $1.5m ($33.1m) $13.2m $21.6m $23.1m $52.4m $69.2m
Unrealized gain (loss) on available-for-sale securities, net of tax of $0, ($20) and $4, respectively ($20k) $30k $22k ($179k) $172k ($10k) $50k ($64k)
Comprehensive income ($18.4m) ($34.0m) $31.9m $75.0m $39.3m $83.3m $71.4m $163.9m $214.3m
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest ($18.1m) ($18.4m) ($34.0m) $33.4m $41.9m $52.7m $104.7m $94.5m $216.3m $283.5m
Net income before income taxes ($18.1m) ($18.4m) ($34.0m) $33.4m $41.9m $52.7m $104.7m $94.5m $216.3m $283.5m
Net Income (Loss) Attributable to Parent ($18.1m) ($18.4m) ($34.0m) $31.9m $75.0m $39.5m $83.1m $71.4m $163.9m $214.3m
Earnings Per Share, Basic ($0.33) $0.31 $0.72 $0.38 $0.80 $0.67 $1.38 $1.75
Earnings Per Share, Diluted ($0.22) ($0.21) ($0.33) $0.30 $0.71 $0.37 $0.75 $0.63 $1.31 $1.68
Basic $102,633,884.00 $102,944,316.00 $103,512,913.00 $103,379,349.00 $103,374,606.00 $106,279,736.00 $118,457,673.00 $122,290,866.00
Diluted $102,633,884.00 $106,020,936.00 $106,242,273.00 $107,795,585.00 $111,375,631.00 $113,753,154.00 $124,943,603.00 $127,257,929.00
Weighted Average Number of Shares Outstanding, Basic $102,633,884.00 102.9m 103.5m 103.4m 103.4m 106.3m 118.5m 122.3m
Weighted Average Number of Shares Outstanding, Diluted $102,633,884.00 106.0m 106.2m 107.8m 111.4m 113.8m 124.9m 127.3m
Research and Development Expense $11.4m $11.4m $19.9m $18.8m $16.5m $16.9m $19.8m $93.2m $12.6m $12.7m
General and Administrative Expense $7.9m $7.3m $15.9m $59.0m $63.1m
Selling, General and Administrative Expense $15.9m $36.9m $44.2m $49.6m $58.2m $133.7m $177.7m $193.8m
Other Nonoperating Income (Expense) $322k $454k $1.3m $1.6m $587k $282k $2.9m $7.7m $21.1m $25.7m
Selling Expense $118.7m $130.7m
Current Income Tax Expense (Benefit) $1.5m ($122k) $3.9m $76.0m
Income Tax Expense (Benefit) $0 $0 $0 $1.5m ($33.1m) $13.2m $21.6m $23.1m $52.4m $69.2m